Novartis’ Tasigna Approved By FDA For CML Patients Resistant to Gleevec
This article was originally published in The Pink Sheet Daily
Executive Summary
The Bcr-Ab1 inhibitor will be available in the U.S. “within days,” the company says.
You may also be interested in...
Novartis Predicts $4 Billion Peak Sales For Gleevec/Tasigna Franchise
Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib’s side-effect profile over Bristol’s Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says.
Novartis Predicts $4 Billion Peak Sales For Gleevec/Tasigna Franchise
Only weeks into Tasigna's launch, Novartis is optimistic doctors will opt for nilotinib’s side-effect profile over Bristol’s Sprycel for Gleevec-resistant CML, Oncology CEO Epstein says.
Bristol Counters Tasigna Approval With “Improved” Sprycel Labeling In CML
Chronic-phase CML patients are recommended to take dasatinib 100 mg once daily, a dose associated with the same efficacy and less fluid retention than twice daily 70 mg dosing.